Skip to content

Celldex Therapeutics, Inc.

CLDX Nasdaq SEC CIK 744218

Follow Celldex Therapeutics Weekly email: filings, results, news

News

4 stories filed under Celldex Therapeutics, grouped into ongoing threads

Phase

Thread · 2 stories

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow

Markets 2 d ago

Celldex Therapeutics earnings up next as Phase III data looms

Earnings 50 d ago also on III

More coverage

Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings

Markets 1 d ago

Why is Celldex Therapeutics stock sliding today?

Markets 1 d ago 2 sources

Next results

NOV5

Q3 2026 results

Thursday · estimated from the filing cadence

Profile

Headquarters: HAMPTON, NJ, United States
Sector: Healthcare
Industry: In Vitro & In Vivo Diagnostic Substances

Peers

Where this page comes from

Profile · SEC EDGAR

Next results · estimated from the filing cadence (SEC EDGAR)

News · 4 stories clustered from the RSS aggregator